Neurogene Balance Sheet Health

Financial Health criteria checks 6/6

Neurogene has a total shareholder equity of $155.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $179.8M and $24.8M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$153.91m
EquityUS$155.01m
Total liabilitiesUS$24.81m
Total assetsUS$179.82m

Recent financial health updates

No updates

Recent updates

Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers

Mar 26

Financial Position Analysis

Short Term Liabilities: NGNE's short term assets ($159.1M) exceed its short term liabilities ($13.1M).

Long Term Liabilities: NGNE's short term assets ($159.1M) exceed its long term liabilities ($11.7M).


Debt to Equity History and Analysis

Debt Level: NGNE is debt free.

Reducing Debt: NGNE had no debt 5 years ago.

Debt Coverage: NGNE has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: NGNE has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies